Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-019-51203-y
Title: An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study
Authors: Chan, A. 
Yeo, A. 
Shwe, M. 
Tan, C.J.
Foo, K.M.
Chu, P.
Khor, C.C.
Ho, H.K. 
Issue Date: 2019
Publisher: Nature Publishing Group
Citation: Chan, A., Yeo, A., Shwe, M., Tan, C.J., Foo, K.M., Chu, P., Khor, C.C., Ho, H.K. (2019). An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study. Scientific Reports 9 (1) : 14570. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-019-51203-y
Rights: Attribution 4.0 International
Abstract: Strong evidence suggests that genetic variations in DNA methyltransferases (DNMTs) may alter the downstream expression and DNA methylation patterns of neuronal genes and influence cognition. This study investigates the association between a DNMT1 polymorphism, rs2162560, and chemotherapy-associated cognitive impairment (CACI) in a cohort of breast cancer patients. This is a prospective, longitudinal cohort study. From 2011 to 2017, 351 early-stage breast cancer patients receiving chemotherapy were assessed at baseline, the midpoint, and the end of chemotherapy. DNA was extracted from whole blood, and genotyping was performed using Sanger sequencing. Patients’ self-perceived cognitive function and cognitive performance were assessed at three different time points using FACT-Cog (v.3) and a neuropsychological battery, respectively. The association between DNMT1 rs2162560 and cognitive function was evaluated using logistic regression analyses. Overall, 33.3% of the patients reported impairment relative to baseline in one or more cognitive domains. Cognitive impairment was observed in various objective cognitive domains, with incidences ranging from 7.2% to 36.9%. The DNMT1 rs2162560 A allele was observed in 21.8% of patients and this was associated with lower odds of self-reported cognitive decline in the concentration (OR = 0.45, 95% CI: 0.25–0.82, P = 0.01) and functional interference (OR = 0.48, 95% CI: 0.24–0.95, P = 0.03) domains. No significant association was observed between DNMT1 rs2162560 and objective cognitive impairment. This is the first study to show a significant association between the DNMT1 rs2162560 polymorphism and CACI. Our data suggest that epigenetic processes could contribute to CACI, and further studies are needed to validate these findings. © 2019, The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/211657
ISSN: 2045-2322
DOI: 10.1038/s41598-019-51203-y
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-019-51203-y.pdf1.23 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

7
checked on Sep 30, 2022

Page view(s)

63
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons